A new mechanism of BRAF activation in human thyroid papillary carcinomas

AUTOR(ES)

Fusco, Alfredo

FONTE

American Society for Clinical Investigation

RESUMO

In this issue of the JCI, Ciampi et al. report the identification of a novel oncogene in patients affected by radiation-associated thyroid papillary carcinomas. This oncogene derives from a paracentric inversion of the long arm of chromosome 7, which results in an in-frame fusion of the N-terminus of the A-kinase anchor protein 9 (AKAP9) gene with the C-terminal catalytic domain (exons 9–18) of the serine-threonine kinase BRAF. The resulting AKAP9-BRAF fusion protein shows constitutive kinase activity, and it is able to transmit mitogenic signals to the MAPK pathways and to promote malignant transformation of NIH3T3 cells.

Documentos Relacionados

• Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer
• p53 expression in anaplastic carcinomas arising from thyroid papillary carcinomas.
• Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas.
• BRAF Mutation Testing of Thyroid Fine-Needle Aspiration Biopsy Specimens for Preoperative Risk Stratification in Papillary Thyroid Cancer
• The long and still uncertain journey of BRAF as a prognostic tool in patients with papillary thyroid cancer